10-Q: Recursion Pharmaceuticals Reports Second Quarter 2024 Results, Highlights Strategic Combination with Exscientia

Recursion Pharmaceuticals announced its second quarter 2024 financial results, alongside a strategic combination with Exscientia, aiming to create a leading TechBio company.

Summary

• Recursion Pharmaceuticals reported a net loss of $97.5 million for the three months ended June 30, 2024, and $188.9 million for the six months ended June 30, 2024.
• The company's operating revenue was $14.4 million for the quarter and $27.9 million for the six-month period, primarily from strategic alliances.
• Research and development expenses were $73.9 million for the quarter and $141.5 million for the six-month period, reflecting investments in platform and pipeline development.
• General and administrative expenses totaled $31.8 million for the quarter and $63.2 million for the six-month period.
• The company's cash and cash equivalents stood at $474.3 million as of June 30, 2024.
• Recursion believes its existing cash will fund operations for at least the next 12 months.
• A significant development is the planned combination with Exscientia, expected to close in early 2025, which aims to create a diverse portfolio of clinical programs and generate significant synergies.
• The combined company is expected to have approximately $850 million in cash and cash equivalents and a cash runway extending into 2027.
• The company completed a public offering of Class A common stock in June 2024, raising net proceeds of approximately $216.4 million.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments such as the strategic combination with Exscientia and the successful capital raise, the company continues to incur significant losses and has a material weakness in internal controls. The future outlook is uncertain, requiring additional capital and facing regulatory risks.

Positives

• Operating revenue increased by 31% in Q2 2024 compared to Q2 2023, indicating growth in strategic partnerships.
• The company successfully raised $216.4 million through a public offering of Class A common stock, strengthening its financial position.
• The strategic combination with Exscientia is expected to create a leading TechBio company with a diverse pipeline and significant synergies.
• The company's BioHive-2 supercomputer is ranked 35th most powerful globally, enhancing its computational capabilities.
• The completion of the genome-scale transcriptomics CRISPR knockout map in HUVEC cells demonstrates progress in platform development.

Negatives

• The company reported a net loss of $97.5 million for Q2 2024, and $188.9 million for the six months ended June 30, 2024, indicating continued operating losses.
• Research and development expenses increased significantly, reflecting the high cost of drug discovery and platform development.
• The company has an accumulated deficit of $1.2 billion as of June 30, 2024.
• The company's disclosure controls and procedures were deemed ineffective due to a material weakness in internal control over financial reporting.

Risks

• The company is subject to risks related to the use of artificial intelligence and machine learning, including inaccuracy, bias, and intellectual property issues.
• Regulatory and legislative developments related to AI could adversely affect the company's use of such technologies.
• The company may not be able to raise additional capital on terms acceptable to it or at all.
• The company's disclosure controls and procedures were deemed ineffective due to a material weakness in internal control over financial reporting.
• The company is involved in legal proceedings that could materially affect its financial position.

Future Outlook

The company expects to continue to incur operating losses and will require additional capital to advance its drug candidates. The company believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditures for at least the next 12 months. The company anticipates the strategic combination with Exscientia will create a leading TechBio company with a diverse pipeline and significant synergies.

Management Comments

• Recursion believes that the Companys existing cash and cash equivalents will be sufficient to fund the Companys operating expenses and capital expenditures for at least the next 12 months.
• The company endeavors to turn drug discovery into a search problem, where we map and navigate biology in an unbiased manner in order to translate insights into more, new and better medicines at higher scale and lower cost to patients.
• The combination with Exscientia would create a diverse portfolio of clinical and near-clinical programs where most of these programs, if successful, could have annual peak sales opportunities in excess of $1 billion.

Industry Context

The announcement of the strategic combination with Exscientia reflects a trend of consolidation and collaboration in the TechBio sector, as companies seek to leverage complementary technologies and pipelines to accelerate drug discovery and development. The focus on AI and machine learning in drug discovery is also a key trend in the industry, with companies like Recursion and Exscientia at the forefront of this approach.

Comparison to Industry Standards

• Recursion's R&D spending as a percentage of revenue is high, which is typical for a clinical-stage biotech company focused on platform development and drug discovery. This is comparable to companies like Relay Therapeutics and Schrödinger, which also invest heavily in technology-driven drug discovery.
• The company's cash burn rate is significant, but this is expected given its stage of development and the capital-intensive nature of its operations. This is similar to other companies in the sector, such as Ginkgo Bioworks and Zymergen, which have also raised substantial capital to fund their operations.
• The strategic combination with Exscientia is a significant move, similar to other mergers and acquisitions in the biotech space aimed at consolidating resources and expertise. This is comparable to the acquisition of companies like Grail by Illumina, which aimed to combine complementary technologies and pipelines.
• The company's focus on AI and machine learning is in line with industry trends, with many companies now incorporating these technologies into their drug discovery processes. This is comparable to companies like Insitro and Atomwise, which are also leveraging AI for drug discovery.

Management Changes

Legal Proceedings

• The company is involved in a lawsuit with Industry Office SLC, LLC, alleging anticipatory repudiation and breach of contract.
• The company has filed counterclaims against Industry Office SLC, LLC, alleging breach of contract and fraudulent misrepresentation.

Stakeholder Impact

• Shareholders will be impacted by the strategic combination with Exscientia, which is expected to create a leading TechBio company.
• Shareholders will be impacted by the company's continued operating losses and the need for additional capital.
• Employees will be impacted by the integration of Exscientia and the potential for synergies and cost reductions.
• Customers and partners will be impacted by the company's continued development of its platform and pipeline.
• Creditors will be impacted by the company's financial performance and its ability to meet its obligations.

Next Steps

• The company expects to complete the strategic combination with Exscientia in early 2025.
• The company expects to share Phase 2 data for REC-994 in September 2024.
• The company expects to share preliminary safety and efficacy results from the adult cohort of the REC-2282 trial in Q4 2024.
• The company expects to initiate a Phase 2 study for REC-3964 in Q4 2024.
• The company expects to submit an IND for REC-1245 in Q3 2024 and initiate a Phase 1/2 study in Q4 2024.
• The company expects to submit an IND for the fibrosis program in early 2025.
• The company expects to complete the delivery of up to 25 multi-modal data packages to Bayer by the end of Q3 2024.

Key Dates

Keywords

TechBio, drug discovery, artificial intelligence, machine learning, clinical trials, genomics, supercomputer, oncology, rare diseases, partnerships, Exscientia, Roche, Bayer, pipeline, data, platform